Early-stage Ovarian Clear Cell Carcinoma (OCCC) Patients at Risk of Recurrence
Condition(s):FIGO Stage IC2 to II Ovarian Clear Cell CarcinomaLast Updated:February 23, 2024Not yet recruiting
Include Studies Not Open or Pending
Condition(s):FIGO Stage IC2 to II Ovarian Clear Cell CarcinomaLast Updated:February 23, 2024Not yet recruiting
Condition(s):Acute PancreatitisLast Updated:November 15, 2022Recruiting
Condition(s):Thromboembolic Venous DiseaseLast Updated:March 5, 2020Not yet recruiting
Condition(s):Renal Cell CarcinomaLast Updated:September 13, 2023Not yet recruiting
Condition(s):Adenoidal HypertrophyLast Updated:December 13, 2023Recruiting
Condition(s):Prostate Cancer; Biochemical RecurrenceLast Updated:March 6, 2023Recruiting
Condition(s):Endometriotic Cyst of OvaryLast Updated:December 2, 2022Recruiting
Condition(s):Breast Cancer; Rare CancerLast Updated:February 13, 2024Recruiting
Condition(s):Glioma; Astrocytoma; Anaplastic Astrocytoma; Oligodendroglioma; Glioblastoma MultiformeLast Updated:February 8, 2024Not yet recruiting
Condition(s):Recurrent Epithelial Ovarian CancerLast Updated:November 24, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.